65,437 trials
End Stage Renal Disease
Primary: Number of Participants With Clinically Significant Cardiac Arrhythmias Using Continuous Cardiac Monitoring Over a 6-month Period With an Implanted Medtronic Reveal ICM…
HHT · Hereditary Hemorrhagic Telangiectasia · Epistaxis
Primary: Change in Epistaxis Severity Score (ESS) — -2.27; -1.16; -2.27; -1.01 score on a scale — p=0.111
Influenza
Primary: Number of Participants Reporting Solicited Injection Site (Local) Reactions — 1421; 2050; 797; 177 Participants
Myocardial Ischemia
Primary: Heme Oxygenase-1 (HO-1) Messenger Ribonucleic Acid (mRNA) Levels (Atrial Tissue) — 392.7; 229.8; 10.8 arbitrary units — p==0.001
Bone Marrow Transplant Infection · Infection in Marrow Transplant Recipients · Respiratory Syncytial Virus Infections
Primary: Percentage of Participants With Progression to Lower Respiratory Tract Infection (LRI) — 8; 30; 10 percentage of participants
Psoriasis
Primary: Percentage Change in Psoriatic Plaque Area — 108.22; 78.89; 84.29; 63.69 percentage change — p=0.3262
Schizophrenia
Primary: Number of Participants With Changes in Fractional Anisotropy (FA) — 13; 9; 7 Participants
Depression
Primary: Whole Brain Total Distribution Volume (VT) - Baseline — 8.2 mL x cm^3
Parkinson's Disease
Primary: Varenicline Occupancy of alpha4beta2* Nicotinic Acetylcholine Receptors — 67.0; 67.9; 65.7; 70.6 percentage of VCN-alpha4beta2* nAChRs
Postoperative Infection · Postoperative Complications
Primary: Bacterial Culture Growth — 32; 33 Participants
Migraine Headache
Primary: Number of Participants With Serious Adverse Events (SAEs) — 5; 3 Participants
Fuchs' Endothelial Dystrophy · Bullous Keratopathy
Primary: Intraocular Pressure — 11; 18 Participants
Nutritional and Metabolic Diseases · Inflammation · Physiological Responses
Primary: Postprandial Insulin Levels for 6 Hours — 63.9; 64.3; 60.2; 56.3 microIU/mL
Obesity
Primary: Number of Subjects With Adverse Events (AEs) — 2; 5; 3; 2 Participants
Prostate Cancer · Prostate Cancer Metastatic · Prostatic Neoplasm
Primary: Salivary Gland Maximal Standardized Uptake Values Corrected for Lean Body Mass (SULmax) for 18F-DCFPyL — 9.9; 15.1 SULmax — p=<0.001